Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained
virological response rate, subject adherence, and subject reported outcomes during and after
treatment of non-cirrhotic genotype 1 chronic hepatitis C subjects aged 18 years and older,
with VIEKIRA PAK (ombitasvir, paritaprevir/r, dasabuvir), with or without RBV (ribavirin).